Table 2

OR for seroprotection in JIA patients in comparison with healthy controls

		Percentage with protective antibody concentrations
Seroprotection	N	JIA	HC	Unadjusted OR (95% CI)	p Value	Adjusted OR^* (95% CI)	p Value
Cohort ≥1986
Measles	1780	93.9	87.4	2.2 (1.4 to 3.5)	0.001	1.4 (0.8 to 2.5)	0.233
Mumps	1783	85.1	85.0	1.0 (0.7 to 1.4)	0.953	0.4 (0.3 to 0.6)	<0.001
Rubella	1782	89.8	90.3	0.9 (0.6 to 1.4)	0.789	0.4 (0.3 to 0.7)	0.001
Diphtheria	1621	90.5	98.5	0.1 (0.08 to 0.3)	<0.001	0.1 (0.06 to 0.2)	<0.001
Tetanus	1621	95.7	99.1	0.2 (0.1 to 0.5)	<0.001	0.1 (0.05 to 0.3)	<0.001
Cohort 1976–85
Measles	791	94.6	91.0	1.7 (0.4 to 7.4)	0.455	2.1 (0.5 to 9.2)	0.319
Mumps	790	81.1	94.8	0.2 (0.1 to 0.6)	0.001	0.1 (0.05 to 0.4)	<0.001
Rubella	791	81.1	98.8	0.05 (0.02 to 0.1)	<0.001	0.03 (0.01 to 0.1)	<0.001
Diphtheria	783	77.1	98.9	0.04 (0.01 to 0.1)	<0.001	0.04 (0.01 to 0.1)	<0.001
Tetanus	783	94.3	99.3	0.1 (0.02 to 0.6)	0.010	0.1 (0.02 to 0.6)	0.010

↵* The OR indicates the odds of having protective antibody levels for JIA patients compared with healthy controls. In logistic regression analysis the OR were adjusted for age and the number of vaccinations at the time of sampling.
HC, healthy controls; JIA, juvenile idiopathic arthritis.